Tiziana Life Sciences PLC (NASDAQ:TLSA) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Zacks has also assigned Tiziana Life Sciences an industry rank of 58 out of 256 based on the ratings given to its competitors.
TLSA has been the topic of a number of recent analyst reports. Laidlaw initiated coverage on shares of Tiziana Life Sciences in a research report on Monday, December 17th. They issued a “buy” rating on the stock. HC Wainwright restated a “buy” rating on shares of Tiziana Life Sciences in a research report on Friday, December 14th.
About Tiziana Life Sciences
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus.
See Also: How prevalent are 12b-1 fees?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.